Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Hypertension is a major risk factor for death and cardiovascular disease (CVD) in patients undergoing chronic haemodialysis (HD), but there is uncertainty surrounding the effects of blood pressure (BP) lowering on this high-risk patient group. METHODS: In a multicenter, prospective, randomized, open-label, blinded-endpoint trial, 469 patients with chronic HD and elevated BP (140-199/90-99 mmHg) were assigned to receive the angiotensin receptor blockade (ARB) olmesartan (at a dose of 10-40 mg daily; n = 235) or another treatment that does not include angiotensin receptor blockers and angiotensin-converting enzyme (ACE) inhibitors (n = 234). The primary outcomes were the following: (i) composite of death, nonfatal stroke, nonfatal myocardial infarction and coronary revascularization and (ii) all-cause death. RESULTS: During a mean follow-up of 3.5 years, the mean BP was 0.9/0.0 mmHg lower in the olmesartan group than in the control group (not significant). A total of 68 patients (28.9%) in the olmesartan group and 67 patients (28.6%) in the control group had subsequent primary composite endpoints [hazard ratio (HR) in the olmesartan group 1.00, 95% confidence interval (CI) 0.71-1.40, P = 0.99]. All-cause deaths occurred in 38 patients (16.2%) in the olmesartan group and 39 (16.7%) in the control group (HR, 0.97; 95% CI, 0.62-1.52, P = 0.91). Olmesartan did not alter the risks of serious adverse events. CONCLUSIONS: BP-lowering treatment with an ARB did not significantly lower the risks of major cardiovascular events or death among patients with hypertension on chronic HD. (Cochrane Renal Group Prospective Trial Register number CRG010600030).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Fox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61171-x · Cited by 789
Cited by
Xie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., Zhao, N., Liu, L., Lv, J., Zhang, H., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.011 · Cited by 479
Flythe, J. E., Chang, T. I., Gallagher, M. P., Lindley, E., Madero, M., Sarafidis, P. A., Unruh, M. L., Wang, A. Y.-M., Weiner, D. E., Cheung, M., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.01.046 · Cited by 278
Self-citationSarafidis, P., Papadopoulos, C. E., Kamperidis, V., Giannakoulas, G., & Doumas, M. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17005 · Cited by 39
Wu, H.-Y., Peng, C.-L., Chen, P.-C., Chiang, C.-K., Chang, C.-J., Huang, J.-W., Peng, Y.-S., Tu, Y.-K., Chu, T.-S., Hung, K.-Y., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177654 · Cited by 33
Predictors of Survival in Chronic Hemodialysis Patients: A 10-Year Longitudinal Follow-Up Analysis
Moromizato, T., Kohagura, K., Tokuyama, K., Shiohira, Y., Toma, S., Uehara, H., Arima, H., Ueda, S., & Iseki, K. (2021) · American Journal of Nephrology · doi:10.1159/000513951 · Cited by 15
Self-citation
Metadata
- Authors
- Iseki, K., Arima, H., Kohagura, K., Komiya, I., Ueda, S., Tokuyama, K., Shiohira, Y., Uehara, H., Toma, S., on behalf of the Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group, Tomiyama, N., Arima, H., Chinen, S., Tokashiki, K., Hirano-Nakasone, A., Nohara, C., Ueda, S., Ueda, S., Kohagura, K., Toma, S., Tana, T., Higa, A., Yamazato, M., Ishida, Y., Tokuyama, K., Nagayoshi, N., Miyagi, S., Asato, T., Kobayashi, R., Shiohira, Y., Yonaha, T., Uezu, Y., Kuwae, N., Nakasato, S., Oshiro, Y., Nashiro, K., Asato, T., Katsuren, H., Kagawa, H., Naika-Geka, K., Higa, T., Ikema, M., Akamine, K., Nishihira, M., Jahana, M., Imai, C., Yonaha, T., Ikemura, M., Uechi, M., Yamazato, M., Yoshihara, K., Arakaki, M., Iha, K., Afuso, H., Kiyuna, S., Shiroma, K., Miyara, T., Itokazu, M., Naka, T., Naka, S., Yamaguchi, E., Uechi, Y., Kowatari, T., Yamada, H., Yoshi, S., Sunagawa, H., Tozawa, M., Uechi, M., Adaniya, M., Afuso, H., Uehara, H., Miyazato, H., Sakuda, C., Taminato, T., Uchima, H., Nakasone, Y., Funakoshi, T., Nakazato, M., Nagata, N., Miyazato, S., Katsuren, H., Miyagi, T., Hirano, H., Iwashiro, K., Sunagawa, T., Yoshida, H., Oshiro, Y., Shimabukuro, T., Oura, T., Henzan, H., Kyan, I., Maeshiro, S., Wake, T., Tagawa, S., Inoue, T., Tokashiki, T., Ishii, H., Miyagi, S., Takishita, S., Saito, S., Shimizu, K., Ohya, Y., & Barzi, F.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-25
- Volume
- 28
- Issue
- 6
- Pages
- 1579-1589
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2147048637
- Cited by
- 99
- References
- 6
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. https://app.cochat.ai/papers/10.1093/ndt/gfs590
- The paper
- Iseki, K., Arima, H., Kohagura, K., Komiya, I., Ueda, S., Tokuyama, K., Shiohira, Y., Uehara, H., Toma, S., on behalf of the Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group, Tomiyama, N., Arima, H., Chinen, S., Tokashiki, K., Hirano-Nakasone, A., Nohara, C., Ueda, S., Ueda, S., Kohagura, K., . . . Barzi, F. (2013). Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfs590
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.